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Objective: Open surgical revascularization for subclavian artery occlusive disease (OD) has largely been supplanted by
endovascular treatment despite the excellent long-term patency of bypass. The indications for carotid-subclavian bypass
(C-SBP) and subclavian transposition (ST) have been recently expanded with the widespread application of thoracic
endovascular aortic repair (TEVAR), primarily to augment proximal landing zones or treat endovascular failures. This
study was performed to determine the outcomes of patients undergoing C-SBP/ST in the context of contemporary
endovascular therapies and evolving indications.
Methods: A prospective database including all procedures performed at a single institution from 2002 to 2012 was
retrospectively queried for patients who underwent subclavian revascularization for TEVAR or OD indications. Patient
demographics and perioperative outcomes were recorded. Patency was determined by computed tomography angiography
in the TEVAR group. Noninvasive studies were used for the OD patients. Life-table methods were used to estimate
patency, reintervention, and survival.
Results: Of 139 procedures identiﬁed, 101 were performed for TEVAR and 38 for OD. All TEVAR patients underwent
C-SBP/ST to augment landing zones (49% preoperative; 41% intraoperative), treat arm ischemia (8% postoperative), or
for internal mammary artery salvage (2%). OD patients had a variety of indications, including failed stent/arm fatigue,
49%; asymptomatic >80% internal carotid stenosis with concurrent subclavian occlusion, 18%; symptomatic cerebrovas-
cular OD, 13%; redo bypass, 8%; and coronary-subclavian steal, 5%. Differences in postoperative stroke and death,
primary patency, or freedom from reintervention were not signiﬁcant. The 30-day postoperative stroke, death, and
combined stroke/death rates were, respectively, 10.8%, 5.8%, and 13.7% for the entire cohort; 8.9%, 7.1%, and 12.9% in
TEVAR patients; and 15.8%, 2.6%, and 15.8% in OD patients. The 1- and 3-year primary patencies were, respectively,
94% and 94% for TEVAR and 93% and 73% for OD patients. Survival was similar between the groups, with an estimated
survival rate of 88% at 1 year and 76% at 5 years.
Conclusions: Stroke risk in this contemporary series of C-SBP/ST performed for TEVAR and OD indications may be
higher than previously reported in historical series. In TEVAR patients, this may be attributed to procedural complexity
of the TEVAR in patients requiring subclavian revascularization. In OD patients, this is likely due to the changing patient
population that requires more frequent concomitant carotid interventions. Despite the short-term morbidity, excellent
bypass durability and equivalent long-term patient survival can be anticipated. (J Vasc Surg 2013;58:901-9.)Subclavian revascularization has historically been per- a 0% to 6% perioperative stroke risk and a 5-year primary
formed on patients with peripheral arterial occlusive disease
(OD) presenting with arm ischemia, vertebrobasilar insufﬁ-
ciency, a threatened left internal mammary artery bypass
graft, or failing ipsilateral hemodialysis access.1,2 Reports
published >2 decades ago, before the endovascular era,
demonstrated that carotid-subclavian bypass (C-SBP) or
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://dx.doi.org/10.1016/j.jvs.2013.04.005patency rate of 82% to 95%,3-5 with slightly higher rates
of perioperative mortality and stroke (4% to 8%) in patients
requiring concomitant revascularization of the carotid bulb
or vertebral artery, or both.6-8 Introduction of angioplasty
or stent treatment of subclavian artery OD led to a shift in
the mid-1990s to the use of open surgical reconstruction
for interventional failures or more complex anatomic
considerations such as preservation of a dominant vertebral
artery, left internal mammary artery graft adjacent to occlu-
sion, or simultaneous severe extracranial carotid or verte-
bral OD.9,10
As the relative frequency of open surgical reconstruc-
tion of subclavian OD has decreased in contemporary prac-
tice,10 the emergence of thoracic endovascular aortic repair
(TEVAR) has expanded the indications for subclavian
revascularization. Although not based on deﬁnitive data,
current consensus guidelines for elective TEVAR recom-
mend routine preoperative subclavian revascularization
when covering the left subclavian artery (LSA).11 Subcla-
vian coverage augments the proximal landing zone, and
revascularization may decrease the risks associated with901
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ischemia, and spinal cord ischemia.11,12
Although subclavian revascularization is reported to
potentially decrease some of the risks associated with
coverage of the subclavian artery, the bypass itself may
increase the risk of stroke, and few series have focused on
the short-term morbidity and outcomes speciﬁcally attrib-
uted to the subclavian revascularization in TEVAR.13
Because of the evolving role of subclavian revascularization
for both OD and TEVAR, this study was undertaken to
determine the contemporary perioperative and long-term
outcomes of patients undergoing C-SBP/ST for TEVAR
and OD in the era of endovascular therapies.
METHODS
Approval for this study was obtained from the Univer-
sity of Florida College of Medicine Institutional Review
Board.
Database and patient cohorts. A prospectively main-
tained operative registry at the University of Florida was
retrospectively queried for all open cervical revasculariza-
tion procedures (bypass or transposition) involving the
subclavian artery for any indication from July 2002 to
June 2012. The analysis included patients with combined
carotid and subclavian OD, innominate lesions, or complex
reconstructions such as C-SBP with concomitant carotid
endarterectomy (CEA). This included patients with extra-
cranial cerebrovascular arterial OD who would require
subclavian-carotid revascularization or vice versa. Patients
treated for OD with percutaneous angioplasty or stent
placement, or both, were evaluated only if they subse-
quently required open surgical reconstruction; otherwise,
patients with isolated endovascular subclavian artery
revascularization were excluded. Patients who underwent
open subclavian revascularization as an adjunct to TEVAR
were also analyzed. We reviewed 607 TEVAR patients, and
identiﬁed 101 (16.6%) who had required subclavian
revascularization. Patients who underwent cardiopulmo-
nary bypass/circulatory arrest for arch replacement were
excluded; however, patients undergoing sternotomy with
innominate/carotid bypass performed at a separate setting
from TEVAR with subclavian revascularization were
included.
Demographics, comorbidities, procedure-related de-
tails, postoperative reintervention, and medication history
were recorded retrospectively. Comorbidities and compli-
cations were deﬁned based on Society for Vascular Surgery
(SVS) reporting standards14,15 Procedural adjuncts for
TEVAR were tabulated and categorized according to
SVS guidelines.16 Adjunctive procedures for OD were
deﬁned as any endovascular or open surgical procedure
that was performed in conjunction with the C-SBP/ST
such as CEA or arch vessel stent. Postoperative stroke
was recorded if the complication was veriﬁed by magnetic
resonance imaging evidence or neurology consultation
documentation, or both. All 30-day strokes due to any
etiology (eg, embolic or hemorrhagic) and any distribution
(anterior or posterior cerebral circulation) or location wererecorded. Mortality events were veriﬁed by query of the
Social Security Death Master File. Study end points
included 30-day stroke, death, combined stroke/death,
all-cause mortality, graft patency, and reintervention.
Clinical practice and operative technique. OD
patients underwent preoperative bilateral brachial and
digital pressure measurements as well as wrist-brachial
index and digital-brachial index calculation. Early in the
experience of OD management, patients underwent
preoperative computed tomography angiography (CTA) or
four-vessel arch aortography, or both, at the operating
surgeon’s discretion. As the practice evolved, virtually all
OD patients underwent preoperative CTA alone. All
TEVAR patients underwent CTA with centerline recon-
struction. Only selected TEVAR patients had preoperative
noninvasive studies.
All C-SBP/ST procedures were performed under
general anesthesia using a variety of conduit choices based
on the operating surgeon’s discretion. The most frequently
used prosthetic conduits were 6- or 8-mm Dacron (Du
Pont, Wilmington, DE) grafts (Vascutek Inc, Terumo,
Ann Arbor, Mich) or 6- or 8-mm polytetraﬂuoroethylene
grafts (Gore-Tex; W.L. Gore & Associates, Flagstaff,
Ariz). In selected cases (eg, redo bypass), autogenous
femoral or saphenous vein was used for reconstruction.
All patients were treated with preoperative antiplatelet
therapy, typically with aspirin (81 mg/d) unless a conﬁrmed
allergy existed, and selected patients with a pre-existing
cardiac stent or concern for symptomatic carotid disease
were maintained on clopidogrel (75 mg/d). Additionally,
patients who were not already receiving long-term statin
therapy were increasingly prescribed postoperative statin
therapy over time.
A supraclavicular incision was used, and permissive
hypertension (mean arterial pressure $70 mm Hg) with
systemic heparinization (100 U/kg bolus; activated clot-
ting time goal of $200 seconds) was instituted before
carotid clamp application. An end-to-side anastomosis to
the subclavian artery distal to the origin of the vertebral
artery was constructed and tunneled in a retrojugular
fashion to complete an end-to-side anastomosis to the
base of the common carotid artery. In cases of ST, the
subclavian artery was mobilized proximal to the vertebral
artery, then ligated, divided, and transposed onto the prox-
imal common carotid artery. Protamine was administered
for anticoagulation reversal at case completion in most
patients. The technical adequacy of the bypass was
conﬁrmed by continuous-wave Doppler insonation and
the presence of a radial pulse, if the patient did not have
pre-existing forearm OD.
Postoperatively, patients underwent serial neurologic
assessment in a surgical intensive care unit with arterial
catheter monitoring. If a change in the preoperative neuro-
logic examination was detected, conﬁrmatory imaging (CT
or MRI with diffusion-weighted imaging, or both) was
obtained with concomitant neurology consultation.
Follow-up protocol. Postoperative graft surveillance
included duplex scanning and pulse examination with
Table I. Overall patient characteristics, medication
history, and comorbidities for patients undergoing
subclavian revascularization for thoracic endovascular
aortic repair (TEVAR) or occlusive disease (OD)
indicationsa
Variablesb
TEVAR
(n ¼ 101)
OD
(n ¼ 38) Pc
Age, years 64 6 12 59 6 13 .05
Male 69 (68) 20 (63) .09
Body mass index 29 6 5 26 6 4 .004
Transpositions 6 (6) 1 (3) NA
Medications
Antiplateletsd 97 (96) 34 (90) .2
Anticoagulatione 13 (13) 8 (21) .3
Statins 61 (62) 25 (66) .7
Comorbidities
Hypertension 89 (88) 32 (84) .6
Dyslipidemia 45 (45) 27 (71) .005
Smoking 43 (43) 34 (89) .0001
Coronary artery disease 33 (33) 23 (61) .003
COPD 17 (17) 16 (42) .02
Diabetes mellitus 15 (15) 11 (29) .06
Renal insufﬁciency 12 (12) 8 (21) .2
Cerebrovascular disease 8 (8) 14 (37) .0001
Peripheral arterial disease 6 (6) 20 (53) .0001
Congestive heart failure 6 (6) 9 (24) .005
COPD, Chronic obstructive pulmonary disease.
aAs expected, the OD cohort had a higher prevalence of cardiovascular risk
factors.
bContinuous data are presented as mean 6 standard deviation and categoric
data as number (%).
cFisher exact, Mann-Whitney, or c2 tests were used when appropriate.
dIncludes aspirin, clopidogrel, or aspirin and clopidogrel.
eIncludes warfarin or low-molecular-weight heparin.
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ments for OD patients at 1 month, 6 months, and annually
thereafter. Patients undergoing subclavian revascularization
with TEVAR were assessed with a serial pulse examination
and postoperative CTA that included the thoracic inlet at
1 month, 6 months, and annually thereafter, unless a
radiographic abnormality dictated otherwise. Bypass grafts
were considered at risk for thrombosis if a 3.5-times step-
up in peak systolic velocity (PSV) was discovered (eg,
highest PSV within stenosis/PSV ratio of proximal normal
vessel), particularly if accompanied by a 0.15 reduction in
the wrist-brachial index or a change in the pulse exami-
nation, or both. Thrombosis was veriﬁed on surveillance
graft duplex scan if no ﬂow was identiﬁed within the graft
or if CTA demonstrated absence of contrast ﬁlling within
the graft.
Patency deﬁnitions of the subclavian reconstruction
were based on SVS reporting standards.14,16 Reinterven-
tion was deﬁned as any endovascular or open surgical
procedure that required a return trip to the operating to
room to treat impending graft failure or thrombosis.
Statistical analysis. Bivariate analysis was performed
on demographics, bypass characteristics, and postoperative
outcomes of OD and TEVAR patients using the Fisher
exact, c2, Mann-Whitney, or Student t-test when appro-
priate. Mortality, patency, and reintervention were
analyzed using Kaplan-Meier life-table methodology and
the Mantel-Cox log-rank test. Multivariable analysis for
predictors of stroke and death was completed using step-
wise logistic regression based on the Akaike information
criterion. This function was bootstrapped 100 times to
ensure robust variable selection, and the model was based
on the variables most often chosen as informative predic-
tors in the bootstrap runs. All data were analyzed with the
R 2.15.0 software (The R Foundation for Statistical
Computing, www.r-project.org), and statistical signiﬁcance
was assumed for P values <.05.
RESULTS
Between 2002 and 2012, 139 patients were identiﬁed
who underwent 144 subclavian revascularization proce-
dures, comprising 137 bypasses and 7 transpositions.
Primary indications for C-SBP/ST included atherosclerotic
OD in 38 (27.3%) and a TEVAR adjunct in 101 (72.7%).
Mean 6 standard deviation age was 62.5 6 12.5 years, and
50 patients (36%) were female. Signiﬁcant differences in
age and comorbidities were present between patients who
underwent subclavian revascularization for OD vs TEVAR
(Table I). No difference in postoperative antiplatelet, anti-
coagulant, or statin use was detected. Overall, 30-day post-
operative stroke, death, and combined stroke/death rates
were, respectively, 10.8% (n ¼ 15), 5.8% (n ¼ 8), and
13.7% (n ¼ 19).
Subclavian revascularization and TEVAR. Of the
101 C-SBP/ST procedures performed as an adjunct to
TEVAR, indication and timing included augmentation of
landing zone (49% preoperatively, 41% intraoperatively),
treatment of arm ischemia (8% postoperatively), or internalmammary artery salvage (2% intraoperatively). Table II
highlights procedure-speciﬁc details and complications
that occurred after TEVAR with subclavian revasculariza-
tion. Notably, 61 patients (60.4%) required one or more
intraoperative adjuncts in addition to C-SBP/ST, including
subclavian embolization in 22, visceral/renal/iliac stent in
16, left common carotid/innominate stent in 15, simul-
taneous EVAR in 13, selective vertebral angiography or
angioplasty, or both, in 4, arch debranching in 3, surgeon-
modiﬁed aortic endograft in 3, transbrachial-femoral wire
in 3, and atrial inﬂow balloon occlusion in 2.
The 30-day postoperative stroke, death, and combined
stroke/death rates were, respectively, 8.9% (n ¼ 9), 7.1%
(n ¼ 7), and 12.9% (n ¼ 13). No signiﬁcant difference in
the rate of stroke or death was detected between various
aortic coverage zone subgroups (P > .99). The combined
stroke/death rate was lower in patients who did not
require an intraoperative adjunct (5.9%) compared with
those who did (16.4%, Fig 1), but this difference was not
statistically signiﬁcant. Details regarding TEVAR indica-
tion, urgency, and needed operative adjuncts for patients
who had postoperative stroke are outlined in Table III.
Subclavian revascularization and OD. Thirty-eight
subclavian revascularization procedures were performed
for OD, with corresponding 30-day postoperative stroke,
Fig 1. Thirty-day stroke/death rate after subclavian revasculari-
zation for thoracic endovascular aortic repair (TEVAR) or occlu-
sive disease (OD) indications stratiﬁed by the need for adjunctive
intervention. Although not statistically signiﬁcant, TEVAR
patients requiring adjunctive intervention in addition to subclavian
revascularization appeared to have a clinical trend toward higher
neurologic morbidity and mortality than those who did not (16.4%
vs 5.9%). Incidence of stroke/death was similar in OD patients
regardless of their need for intraoperative adjuncts (15.4% with and
16.0% without).
Table II. Pathologic indication, operative details,
and outcomes of patients undergoing subclavian
revascularization for thoracic endovascular aortic
repair (TEVAR) indicationsa
Feature
No. (%) or
mean 6 SD (n ¼ 101)
ASA classiﬁcation 3 or 4 100 (99)
Urgent/emergent 37 (36.6)
Pathology
Aneurysm 48 (47.5)
Chronic dissection 18 (17.8)
Acute dissection 16 (15.8)
Other 16 (15.8)
Transection 3 (2.9)
Stents, No.
1 39 (38.6)
2 36 (35.6)
$3 26 (25.7)
Proximal coverage zone
0 17 (16.8)
1 10 (9.9)
2 74 (73.2)
Conduit type
Dacron 86 (85.1)
Polytetraﬂuoroethylene 15 (14.8)
Intraoperative adjunct 61 (60.4)
Any complication 36 (35.6)
Spinal cord ischemia 6 (5.9)
Stroke 9 (8.9)
Death 7 (6.9)
Length of stay, days 9.7 6 10.3
ASA, American Society of Anesthesiologists.
aNote that 36% of cases were performed for urgent or emergent indications
and 60% required some form of intraoperative adjunct to successfully
complete the TEVAR.
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15.8% (n ¼ 6), 2.6% (n ¼ 1), and 15.8% (n ¼ 6). Peri-
procedural variables and outcomes of the OD C-SBP/ST
subgroup are further delineated in Table IV. Speciﬁc
indications for cervical reconstruction involving the
subclavian artery included failed stent/arm fatigue, 49%;
asymptomatic >80% internal carotid stenosis with
concurrent subclavian occlusion and arm ischemia, 18%;
symptomatic carotid or vertebral OD, or both, with severe
proximal common carotid OD, 13%; redo bypass with arm
ischemia, 8%; and coronary-subclavian steal, 5%. Among
these patients, 13 (34.2%) required one or more adjunctive
procedures, including simultaneous carotid endarterec-
tomy or bypass in 7, retrograde common carotid/innom-
inate stenting in 5, or vertebral artery reimplantation in 2.
The rates of 30-day stroke, death, and combined stroke/
death were not signiﬁcantly different between patients who
required an adjunctive revascularization procedure
compared with those undergoing C-SBP/ST alone (P >
.99, Fig 1).
Urgent or emergent presentations were common in
OD patients (n ¼ 17; 45%) and included cerebrovascular
symptoms in seven, arm ischemia in seven, and cardiac
symptoms in three. Stroke rate in the urgent patients was
29% compared with 5% of those undergoing electivereconstruction (P ¼ .05). OD patients who suffered
a stroke postoperatively had an overall greater number of
comorbidities than the remainder of the cohort (6.5 6
2.8 vs 4.9 6 2.5; P ¼ .08). For OD patients who had post-
operative stroke, speciﬁcs regarding indication for cervical
revascularization, urgency, and need for operative adjuncts
are further detailed in Table V.
Patency and reintervention. Mean follow-up time
was 16.1 6 24.8 months (median, 3.9) for the entire
cohort, 12.0 6 19.4 months (median, 2.0 months) for
TEVAR patients, and 26.9 6 33.5 months (median, 13.9
months) for OD patients. Radiographic follow-up time in
patients with available imaging was 14.5 6 21.1 months
(median, 6.4 months) for TEVAR patients and 32.5 6
34.7 months (median, 25.6 months) for OD patients. Figs
2 and 3 highlight the primary patency and freedom from
reintervention after C-SBP/ST. The 1-year and 3-year
primary patencies were, respectively, 93% and 73% for
OD patients and 94% and 94% for TEVAR patients.
Similarly, the corresponding 1-year and 3-year rates of
freedom from reintervention were 93% and 73% for OD
patients and 94% and 94% for TEVAR patients.
Survival after subclavian revascularization. Fig 4
depicts the overall 5-year survival for OD and TEVAR
patients undergoing C-SBP/ST. For all patients, the esti-
mated 1-year survival was 88% (95% conﬁdence interval,
81%-93%) and the 5-year survival was 76% (95% conﬁdence
interval, 66%-83%). Corresponding 5-year actuarial survival
estimates were 74% for TEVAR and 76% for OD patients
(P ¼ .4).
Multivariable analysis of stroke and death. Multi-
variable logistic regression analysis was completed to iden-
tify factors predictive of 30-day stroke/death for all
patients undergoing subclavian revascularization. C-SBP/
ST performed as an adjunct to TEVAR, presence of
Table III. Details regarding the index thoracic endovascular aortic repair (TEVAR) indication, procedural details, stroke
timing, distribution, and outcomesa
Patient Indication Urgency Bypass operation TEVAR adjunct Stroke location/timing Outcome
1 Thoracic aneurysm Elective L CCA-SCA;
Pre-op
LSCA embolization;
R iliac conduit
L cerebellar; POD#0 Death on POD#6
2 Kommerell’sb Elective R CCA-SCA;
Pre-op
None Bilateral anterior
hemisphere;
POD#0
Full recovery
3 Thoracic aneurysm Elective R/L CCA-CCA
þ L CCA-SCA;
Intra-op
R iliac conduit Bilateral anterior
hemisphere;
POD#0
Death; 2.2 months
4 Thoracoabdominal
aneurysm
Elective Arch debranching;
Pre-op
Direct aortic conduit L MCA; POD#0 Residual R arm
weakness; home
5 Thoracic aneurysm Elective L CCA-SCA;
Intra-op LIMA
salvage
R transbrachial
femoral wire; R
femoral TEA
R cerebellar; POD#2 Death; 2.6 months
6 Acute dissection Urg/Symp L CCA-SCA;
Intra-op
Vertebral
transposition
L cerebellar; POD#0 Death on POD#9
7 Chronic dissection/
aneurysm
Elective L CCA-SCA;
Pre-op
None R MCA Death on POD#15
8 Aortic coarctation
pseudoaneurysm
Elective L CCA-SCA
transposition;
Intra-op
R atrial inﬂow
occlusion
R occipital; POD#14 Full recovery
9 Chronic dissection/
aneurysm
Elective L CCA-SCA;
Intra-op
L renal stent graft L MCA; POD#1 Full recovery
CCA, Common carotid artery; L, left; LIMA, left internal mammary artery; MCA, middle cerebral artery; POD, postoperative day; R, right; SCA, subclavian
artery; TEA, thromboendarterectomy.
aFive of the nine stroke patients (55.5%) died #3 months of the index TEVAR that required subclavian revascularization.
bKommerell diverticulum (dysphagia lusoria).
Table IV. Indications, procedure-related details, and
outcomes of patients with occlusive disease (OD)
indications undergoing subclavian revascularizationa
Feature
No. (%) or
mean 6 SD (n ¼ 38)
ASA classiﬁcation 3 or 4 35 (92.1)
Urgent/emergent 17 (44.7)
Previous subclavian stent 16 (42.1)
Redo bypass 9 (23.7)
Pathology
OD 32 (84.2)
Hemodialysis access salvage 3 (7.8)
LIMA salvage 3 (7.8)
Conduit type
Polytetraﬂuoroethylene 22 (57.9)
Dacron 7 (18.4)
Femoral vein 7 (18.4)
Saphenous vein 2 (5.3)
Intraoperative adjunct 13 (34.2)
Any complication 13 (34.2)
Stroke 6 (15.8)
Death 4 (10.5)
Length of stay, days 5.3 6 9.5
ASA, American Society of Anesthesiologists; LIMA, left internal mammary
artery; SD, standard deviation.
aThe presentation was urgent or emergent in 44%, and 34% required
adjunctive procedure.
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mg/dL), and coronary artery disease (CAD; deﬁned
according to SVS reporting guidelines14-16) were included
in the ﬁnal model, which predicted the composite outcomecorrectly in 90% of patients (area under the curve ¼ 0.72).
Renal insufﬁciency increased the risk of stroke/death
5.8-fold (95% CI, 1.8-fold to 18.50-fold; P ¼ .003),
whereas CAD was associated with a 3.6-fold increase in the
composite outcome (95% CI, 1.2-fold to 11.7-fold;
P ¼ .03). TEVAR was included in the model but was
not an independent predictor of stroke/death (odds ratio,
1.5; P ¼ .5).
DISCUSSION
The results of this contemporary series of C-SBP/ST
procedures performed in the endovascular era demonstrate
a higher rate of stroke in OD patients compared with
historical reports, with many patients having undergone
previous endovascular or open interventions. This study
also suggests that the perioperative stroke risk may be
higher in TEVAR patients when subclavian revasculariza-
tion is performed with other adjunctive therapies. Despite
an increased rate of perioperative neurologic morbidity
under these circumstances, patency of C-SBP is excellent,
and long-term survival does not appear to be negatively
affected by these complications.
Signiﬁcant subclavian artery OD ($15 mm Hg inter-
arm pressure difference) is estimated to be present in 2%
to 7% of the general population; however, the true preva-
lence is not known because most lesions are found inciden-
tally in asymptomatic patients.17-19 Historically, direct
repair of subclavian OD was performed through a thora-
cotomy,1,3 but the high morbidity and mortality of this
approach led to increased adoption of extra-anatomic
Table V. Details regarding the indication, technical conduct, stroke timing, distribution, and outcomes for patients
experiencing a stroke after undergoing cervical reconstruction involving subclavian revascularizationa
Patient Indication Urgency Bypass operation Adjunct Stroke location/timing Outcome
1 Right subclavian
occlusion, innominate
pseudoaneurysm,
failed stent for arm
fatigue
Urg/symp R CCA-SCA Innominate stent
graft subclavian
embolization
R MCA; POD#0 R leg weakness,
living at home
2 Left carotid stump
syndrome and
vertebral stenosis
Urg/symp L SCA-ICA L CEA/vertebral
reimplant
L pontine; POD#0 Full recovery
3 Global hypoperfusion Elective Redo L CCA-SCA L CEA L MCA; POD#0 Death; POD#14
4 Left carotid occlusion Urg/symp L SCA-CCA None L MCA; POD#24 Full recovery
5 Global hypoperfusion Elective SCA-ICA None R occipital; POD#14 Full recovery
6 VBI Elective L CCA-SCA None L cerebellar; POD#0 Full recovery
CCA, Common carotid artery; CEA, carotid endarterectomy; ICA, internal carotid artery; L, left; MCA, middle cerebral artery; OD, occlusive disease; POD,
postoperative day; SCA, subclavian artery; VBI, vertebrobasilar insufﬁciency.
aNotably, three patients required the subclavian artery as the donor vessel to the bypass due to extracranial carotid OD. One of the six patients (16.7%) died
postoperatively; however, the remaining patients experienced neurologic recovery.
Fig 2. Primary patency of subclavian revascularization is shown for
thoracic endovascular aortic repair (TEVAR) and occlusive disease
(OD) indications. The two groups have equivalent 1-year and
3-year primary patency. SE, Standard error.
Fig 3. Freedom from reintervention after subclavian revasculari-
zation for thoracic endovascular aortic repair (TEVAR) and
occlusive disease (OD) indications is depicted. No difference in the
need for reintervention is noted at 1 and 3 years between the two
groups. SE, Standard error.
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bypass, and carotid-ST.4,5,7 Indeed, C-SBP/ST quickly
supplanted virtually all direct or alternative extra-
anatomic (eg axilloaxillary or femoroaxillary bypass) strate-
gies for open surgical reconstruction of subclavian OD after
multiple reports documented low 30-day major morbidity
(2%-15%) and mortality (0%-2%) as well as excellent
5-year primary patency (82%-95%).4,5,10,18,20
The outcomes after C-SBP/ST have most commonly
been described in the context of an isolated subclavian
revascularization without adjunctive procedures. Morbidity
in that setting is primarily related to cranial nerve injury
(1%-11%), cardiovascular events (1%-8%), hematoma
(0.2%-2%), lymph leak (0%-9%), and embolic complications
(0%-3%).5,20 The stroke risk with an isolated C-SBPwithout adjunctive procedures has consistently been re-
ported to be 0% to 6%.5,20-22 Of note, simultaneous signif-
icant (>70%) vertebral or carotid OD, or both, is
reportedly present in 58% to 75% of patients,21 which can
often necessitate more complex arterial reconstructions.
Staged or concomitant carotid reconstruction with C-
SBP/ST has been shown to increase the perioperative
stroke risk. Risty et al23 reported a review of 12 studies,
comprising 765 patients, with a 30-day stroke rate of
4.7% when C-SBP/ST was performed with concomitant
ipsilateral CEA compared with 0.3% when C-SBP/ST
was performed alone (P < .001). Further, Sullivan et al24
reported a 14% rate of stroke in patients with tandem
carotid bifurcation and proximal common carotid OD
Fig 4. Overall patient survival after subclavian revascularization
for thoracic endovascular aortic repair (TEVAR) and occlusive
disease (OD) indications is demonstrated. Notably, despite
elevated rates of neurologic morbidity compared with historical
controls, 5-year survival is good and equivalent between the two
cohorts.
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innominate stenting. In our series, 11 patients (28.9%)
similarly required simultaneous CEA or carotid/innomi-
nate stent placement, or both, along with their C-SBP,
and two (18.2%) sustained nondisabling strokes, indicating
that the addition of adjuncts and procedural complexity,
not surprisingly, increases the risk of these procedures.
With the advent of endoluminal therapies in the 1990s,
open surgical reconstruction for supra-aortic trunk disease
has been increasingly performed for endovascular failures
or for patients with complex anatomy.10 This trend is
evident in our series; prior subclavian stent placement or
C-SBP, or both, was unsuccessful in 16 patients (42%).
The negative effect of prior failed endovascular interven-
tion on C-SBP is not known, but notably, two of the three
postoperative graft thrombosis events in our OD cohort
occurred in patients whose previous endovascular interven-
tion was not successful. Despite this, the patency of C-
SBP/ST was excellent in our series of OD patients, with
primary patency of 93% at 1 year and 73% at 3 years.
Although these estimates seem lower than those after
subclavian revascularization with TEVAR (94% and 94%,
respectively), the accuracy of the 3-year OD primary
patency estimates were limited by small numbers and a stan-
dard error >10% beyond 30 months.
The relatively high rate in our series of prior failed
subclavian intervention and the need for simultaneous
carotid or vertebral reconstruction, or both, suggests that
these patients have more advanced disease and greater
atherosclerotic disease burden than those in historical
series. In addition, a substantial proportion of our ODpatients (45%) presented urgently with cerebrovascular,
cardiac, or arm ischemia symptoms, which likely contrib-
uted to the higher-than-expected perioperative stroke
rates. Indeed, 29% of OD patients who underwent urgent
C-SBP had a postoperative stroke compared with 5% of
those undergoing elective reconstruction, which was signif-
icantly different (P ¼ .05). Further, OD patients who sus-
tained a postoperative stroke had an overall greater number
of comorbidities than the rest of the cohort (6.5 6 2.8 vs
4.9 6 2.5; P ¼ .08).
TEVAR has become an increasingly common indica-
tion for C-SBP/ST during the last decade, and up to
40% of all TEVAR patients require LSA coverage for
successful repair. Coverage of the subclavian artery has
been associated with a 3% to 8% perioperative stroke, spinal
cord ischemia, or death rate.25 The 2010 SVS consensus
statement11 supports preemptive subclavian revasculariza-
tion, but this suggestion is based on low-quality evidence
and remains controversial. Our bias is to revascularize the
subclavian artery, particularly in the patient who is felt to
be at high risk for spinal cord ischemia (eg, extensive
TEVAR coverage, prior infrarenal aortic repair, etc) or
who has a dominant left vertebral artery. In patients with
short aortic coverage (<150 mm) and a nondominant
left vertebral artery with no other indications for revascular-
ization, we will cover the LSA without revascularization.
Owing to these considerations, our practice has experi-
enced a 2.5-fold greater use of C-SBP/ST for TEVAR
compared with OD indications during a 10-year interval.
Again, conﬂicting data exist regarding stroke risk with
the addition of C-SBP/ST to TEVAR, and stroke after
TEVAR is known to portend a particularly poor progno-
sis, with in-hospital mortality rates ranging from 5% to
33%.26-28 Some have endorsed a more selective LSA revas-
cularization strategy because of the concern of elevated
stroke risk.29,30
In our series, the perioperative stroke and death rates
were, respectively, 8.9% and 7% after TEVAR with
C-SBP/ST. Although somewhat higher than previously re-
ported, the mortality rate may be explained by the signiﬁ-
cant proportion of patients (37%) with emergent/
ruptured or urgent/symptomatic presentations for a variety
of indications, including acute dissection and contained
aneurysm rupture, among others. In addition, 60% of
TEVAR patients required additional intraoperative
adjuncts along with C-SBP/ST. A need for other intrao-
perative adjuncts is likely a marker of more extensive aortic
disease and thus may be associated with increased neuro-
logic risk. Patients who required additional adjuncts had
a trend toward an increased perioperative stroke/death
rate (16.4%) compared with those who did not (5.9%;
P ¼ .2).
Independent predictors of postoperative stroke/death
identiﬁed among the entire cohort of C-SBP/ST patients
were preoperative renal insufﬁciency and coronary artery
disease (CAD), increasing the risk of the composite
outcome by nearly sixfold and fourfold, respectively. Inter-
estingly, the surgical indication for C-SBP/ST (TEVAR
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Instead, the occurrence of postoperative stroke and death
seemed to be primarily dictated by patient-related factors
and the overall complexity of their procedure.
This study has several limitations, including that this is
a single-center, retrospective study with limited patient
numbers and events for analysis. This leads to the possi-
bility of type II error and limits the conclusions we can
draw from the multivariable analysis. Moreover, multiple
indications and procedural urgency categories were
analyzed, which might have contributed additional con-
founding to the observed results.
Although the results of this analysis will undoubtedly
raise concerns, particularly regarding the outcome of the
subclavian revascularization for OD subgroup, we high-
light that the evolution of the type and complexity of the
procedures represented in this report are vastly different
than those for historical controls.
Finally, there was no standardized treatment algorithm
dictating when C-SBP/ST was performed as an adjunct to
TEVAR and when carotid/vertebral reconstruction was
performed as an adjunct to C-SBP/ST in OD patients.
This further limits the conclusions that can be made
regarding the effects that these adjuncts may have on
outcomes.
CONCLUSIONS
Stroke risk in this contemporary series of C-SBP/ST
performed for TEVAR and OD may be higher than previ-
ously reported in historical series. However, this seems to
be attributable primarily to patient-related factors and the
complexity of the procedure in both TEVAR and OD
patients. Despite the short-term morbidity, excellent
bypass durability and equivalent long-term patient survival
can be anticipated.
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